PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Heart. 1996 December; 76(6): 507–509.
PMCID: PMC484603

Fludrocortisone in the treatment of hypotensive disorders in the elderly.

Abstract

OBJECTIVE: To evaluate tolerance of fludrocortisone in older patients with hypotensive disorders. DESIGN: Prospective case series. SETTING: Syncope clinic. PATIENTS: 64 Consecutive patients over 65 years (mean age 80 years) with one or more hypotensive disorders (orthostatic hypotension, vasodepressor carotid sinus syncope, and/or vasodepressor neurocardiogenic syncope. INTERVENTIONS: Fludrocortisone in daily doses of 100 micrograms [corrected] (72%), 50 micrograms [corrected] (27%), and 200 micrograms [corrected] (one patient). MAIN OUTCOME MEASURES: Adverse events, treatment withdrawal. RESULTS: During follow up 13 patients died of unrelated causes. Of the remainder 33% discontinued fludrocortisone at a mean of five months. Reasons for discontinuing treatment were hypertension, five; cardiac failure, four; depression, three; oedema, three; and unspecified, two. In those who continued treatment supine systolic and diastolic blood pressure did not differ significantly from baseline (follow up two to 21 months). Hypokalaemia developed in 24% at a mean of eight months; in no case was treatment withdrawn because of hypokalaemia. CONCLUSION: Fludrocortisone, even in low doses, is poorly tolerated in the long term in older patients with hypotensive disorders.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (567K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979 Jul 12;301(2):68–73. [PubMed]
  • Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985 Sep-Oct;8(5):491–498. [PubMed]
  • Kapoor WN. Diagnostic evaluation of syncope. Am J Med. 1991 Jan;90(1):91–106. [PubMed]
  • McIntosh SJ, Lawson J, Kenny RA. Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly. Am J Med. 1993 Aug;95(2):203–208. [PubMed]
  • McIntosh S, Da Costa D, Kenny RA. Outcome of an integrated approach to the investigation of dizziness, falls and syncope in elderly patients referred to a 'syncope' clinic. Age Ageing. 1993 Jan;22(1):53–58. [PubMed]
  • Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. Br Med J. 1976 Apr 10;1(6014):872–874. [PMC free article] [PubMed]
  • da Costa D, McIntosh S, Kenny RA. Benefits of fludrocortisone in the treatment of symptomatic vasodepressor carotid sinus syndrome. Br Heart J. 1993 Apr;69(4):308–310. [PMC free article] [PubMed]
  • Watt SJ, Tooke JE, Perkins CM, Lee MR. The treatment of idiopathic orthostatic hypotension: a combined fludrocortisone and flurbiprofen regime. Q J Med. 1981 Spring;50(198):205–212. [PubMed]
  • Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab. 1989 Jun;68(6):1051–1059. [PubMed]
  • Lopes de Faria SR, Zanella MT, Andriolo A, Ribeiro AB, Chacra AR. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther. 1988 Dec;44(6):670–674. [PubMed]
  • Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988 Jun;38(6):951–956. [PubMed]
  • Ward C, Kenny RA. Observations on midodrine in a case of vasodepressor neurogenic syncope. Clin Auton Res. 1995 Oct;5(5):257–260. [PubMed]
  • Biaggioni I, Zygmunt D, Haile V, Robertson D. Pressor effect of inhaled ergotamine in orthostatic hypotension. Am J Cardiol. 1990 Jan 1;65(1):89–92. [PubMed]
  • West JN, Stallard TJ, Dimmitt SB, Smith SA, Williams A, Littler WA. Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy-Drager syndrome). Q J Med. 1990 Feb;74(274):209–213. [PubMed]
  • Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med. 1994 Oct;97(4):366–368. [PubMed]
  • Matsubara S, Sawa Y, Yokoji H, Takamori M. Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):994–997. [PMC free article] [PubMed]
  • Sra JS, Murthy VS, Jazayeri MR, Shen YH, Troup PJ, Avitall B, Akhtar M. Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol. 1992 Feb;19(2):402–408. [PubMed]
  • Milstein S, Buetikofer J, Dunnigan A, Benditt DG, Gornick C, Reyes WJ. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol. 1990 Jun 1;65(20):1339–1344. [PubMed]

Articles from Heart are provided here courtesy of BMJ Publishing Group